Chimerix to Speak Today at The White House Cancer Moonshot Forum

Core Insights - Chimerix's Chief Scientific Officer, Dr. Joshua E. Allen, will discuss the impact of the Biden Cancer Moonshot on brain cancer and rare pediatric disease drug development [1][2] - The Biden Cancer Moonshot has improved cancer diagnosis and treatment, particularly in enhancing health equity in clinical trials and expanding patient navigation services for pediatric cancer [2] - Chimerix submitted a New Drug Application (NDA) for dordaviprone to the U.S. FDA, seeking accelerated approval for recurrent H3 K27M-mutant diffuse glioma, with a potential Prescription Drug User Fee Act (PDUFA) action date in Q3 2025 [3] Company Overview - Chimerix is a biopharmaceutical company focused on developing medicines that improve and extend the lives of patients with deadly diseases [4] - The company's lead clinical program, dordaviprone, is in development for H3 K27M-mutant glioma, and it is conducting Phase 1 dose escalation studies of ONC206 [4] Product Information - Dordaviprone (ONC201) is a first-in-class small molecule imipridone that targets the mitochondrial protease ClpP and dopamine receptor D2 (DRD2) [5]